



**National Institute for
Health and Clinical Excellence**

MidCity Place
71 High Holborn
London
WC1V 6NA

Tel: 0845 003 7780
Fax: 0845 003 7784

Email: nice@nice.org.uk
www.nice.org.uk

Roche products Ltd

11 June 2009

Dear Sirs

Final Appraisal Determination: Bevacizumab (first line) sorafenib (first and second line) sunitinib (second line) and temsirolimus (first line) for the treatment of advanced and/or metastatic renal cell carcinoma

Thank you for your response to the initial scrutiny of your appeal lodged against this FAD. This letter represents the final decision on initial scrutiny.

Point 3

In so far as you feel there may be evidence you did not see this would be a valid ground one appeal point. Otherwise it would be a ground two point. I agree it should go forward on either basis.

Conclusion

This is the final decision on initial scrutiny. The valid appeal points are Ground one: 1, 2, 3, Ground 2, 3, 4, Ground 3 1/5.

Yours sincerely


Appeals Committee Chair

National Institute for Health and Clinical Excellence